Abstract
Indiplon is a nonbenzodiazepine hypnotic being developed for the treatment of insomnia by Neurocrine Biosciences Inc. It is an allosteric modulator of the γ-amino butyric acid-α receptor complex with very high affinity for the α1 subunit, which is associated with hypnotic activity, sedation and amnesia. Indiplon has been developed in two different formulations: an immediate-release version targeting sleep initiation insomnia and a modified-release version addressing sleep maintenance insomnia. Early results from clinical trials indicate that both formulations are well tolerated and effective at improving objective and subjective measures of sleep.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
